Physician profile
Shawn Peffall
NPI 1457318933
$1,273.29
in general payments reported to CMS, 2019-2025
25 companies · $247 in 2025
The $247 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $581 · 2020: $50.97 · 2023: $151 · 2024: $244 · 2025: $247.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $641.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $641.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $184.99 | 2023-2025 | |
| Amgen INC. | $144.14 | 2019-2025 | Otezla, Repatha, Otezla |
| Novo Nordisk INC | $130.40 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Exact Sciences Corporation | $76.62 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $67.51 | 2019-2025 | Trelegy Ellipta, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $64.12 | 2019 | |
| Janssen Pharmaceuticals, INC | $59.53 | 2019-2020 | |
| Lilly USA, LLC | $56.24 | 2019 | |
| Allergan, INC. | $55.14 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $54.24 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $52.31 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $40.14 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $35.39 | 2024-2025 | Camzyos |
| Merck Sharp & Dohme LLC | $34.65 | 2019 | |
| Sunovion Pharmaceuticals INC. | $33.07 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerin Medical INC. | $25.36 | 2025 | |
| Mylan Specialty L.P. | $23.30 | 2019 | |
| Neos Therapeutics, LP | $21.19 | 2019 | |
| Novartis Pharmaceuticals Corporation | $19.27 | 2023 | |
| Valeritas, INC. | $18.48 | 2019 | |
| Astellas Pharma US INC | $18.32 | 2024 | Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $17.25 | 2019 | |
| Abbott Laboratories | $14.15 | 2023 | Freestyle Libre 3 |
| Gilead Sciences, INC. | $14.13 | 2019 | |
| Alexion Pharmaceuticals, INC. | $13.35 | 2023 | Strensiq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shawn Peffall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.